Galectin-1 Expression Is Associated with the Response and Survival Following Preoperative Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

Shau-Hsuan Li 1, Yen-Hao Chen 1, Hung-I Lu 2, Chien-Ming Lo 2, Chao-Cheng Huang 3, Yu-Ming Wang 4 and Eng-Yen Huang 4,*

1 Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; lee0624@cgmh.org.tw (S.-H.L.); alex2999@cgmh.org.tw (Y.-H.C.)
2 Department of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; luhungi@cgmh.org.tw (H.-I.L.);
t123207424@cgmh.org.tw (C.-M.L.)
3 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; huangcc@cgmh.org.tw
4 Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; scorpion@cgmh.org.tw
* Correspondence: huangengyen@gmail.com; Tel.: +886-7-7317123 (ext. 7000); Fax: +886-7-7322813

Simple Summary: Galectin-1 has been found to be involved in therapeutic resistance in a variety of cancers. However, the prognostic significance of galectin-1 expression in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with chemoradiotherapy remains unknown. Immunohistochemically, we observed that galectin-1 overexpression in pretreatment biopsied specimens was significantly associated with a lower pathological complete response rate, worse overall survival and disease-free survival in 93 patients with locally advanced ESCC receiving preoperative chemoradiotherapy. Our findings suggest that galectin-1 may be a potential therapeutic target for patients with ESCC treated with preoperative chemoradiotherapy.

Abstract: The galectin-1 has been found to be involved in poor outcomes after treatment of a variety of cancers. To the best of our knowledge, however, the significance of galectin-1 expression in the sensitivity to chemoradiotherapy (CCRT) of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains unclear. Expression levels of galectin-1 were evaluated by immunohistochemistry and correlated with the treatment outcome in 93 patients with locally advanced ESCC who received preoperative CCRT between 1999 and 2012. Galectin-1 expression was significantly associated with the pathological complete response (pCR). The pCR rates were 36.1% and 13.0% (p = 0.01) in patients with low and high galectin-1 expression, respectively. Univariate analyses revealed that galectin-1 overexpression, clinical 7th American Joint Committee on Cancer (AJCC) stage III and a positive surgical margin were significant factors of worse overall survival and disease-free survival. In multivariate analyses, galectin-1 overexpression and a positive surgical margin represented the independent adverse prognosticators. Therefore, galectin-1 expression both affects the pCR and survival in patients with locally advanced ESCC receiving preoperative CCRT. Our results suggest that galectin-1 may be a potentially therapeutic target for patients with ESCC treated with preoperative CCRT.

Keywords: esophageal cancer; squamous cell carcinoma; Galectin-1; chemoradiotherapy; pathological complete response

1. Introduction

The treatment outcomes of patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing surgery alone is poor [1,2]. Therefore, concurrent chemora-
diotherapy (CCRT) followed by esophagectomy has been suggested for these patients in order to improve the outcome [3]. However, the necessity for an esophagectomy after CCRT remains unclear. In fact, phase III clinical trials [3,4] demonstrated that an esophagectomy may be unnecessary for those patients who respond well to CCRT. There are 20–40% patients who can achieve a pathological complete response (pCR) following preoperative CCRT. Therefore, these patients with pCR have a significantly improved survival [5–7]. However, there is still at least one half of patients without pCR after CCRT. Therefore, it is important to explore the biomarkers involved in the resistance to CCRT and identify patients with a good response to CCRT to avoid potential perioperative complications.

Galectins are members of a lectin family and an affinity for ß-galactose-containing oligosaccharides [8]. There are 15 different galectins found. Galectin-1 is widely expressed in many tissues and has many cellular functions, such as proliferation [9], cellular signaling, adhesion, migration [10] and apoptosis [11]. In the tumor microenvironment, galectin-1 has been shown to be involved in immune suppression [11], tumor angiogenesis [12] and metastasis [13]. Previous studies showed that galectin-1 was regulated by hypoxia [14–16], and tumor hypoxia is well-known to be related to resistance to radiotherapy or chemotherapy [17]. Galectin-1 is involved in the resistance to radiotherapy or chemotherapy in several types of cancer including squamous cell carcinoma of the uterine cervix [18], hepatocellular carcinoma [19], glioblastoma [20,21], epithelial ovarian cancer [22] and lung carcinoma [23,24]. However, the significance of galectin-1 expression to the sensitivity of preoperative CCRT in patients with locally advanced ESCC remains unclear. The aim of this study was to investigate whether galectin-1 expression can predict the sensitivity of CCRT in patients with locally advanced ESCC. Thus, we investigated the galectin-1 expression by immunohistochemistry (IHC) and demonstrated its role in 93 patients with locally advanced ESCC treated with preoperative CCRT.

2. Materials and Methods

2.1. Patient Population

This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB number: 20210009B0), Kaohsiung, Taiwan, R.O.C. From January 1999 to December 2012, patients who had a diagnosis of esophageal cancer and received treatment at Kaohsiung Chang Gung Memorial Hospital were reviewed retrospectively. During this period, 769 patients diagnosed with esophageal cancer were treated at our hospital, and their medical records were reviewed. The inclusion criteria of this study were as follows: (1) Pathologically confirmed diagnosis of ESCC and excluding other histology type; (2) Patients received preoperative CCRT followed by esophagectomy; (3) Patients had available pretreatment specimens of biopsy for IHC; (4) 7th American Joint Committee on Cancer (AJCC) clinical stage II or III; (5) Eastern Cooperative Oncology Group performance status 0–1. The exclusion criteria of this study were as follows: (1) The presence of distant metastases; (2) Cervical location of esophageal cancer; (3) Patients had synchronous cancer such as head and neck cancer; (4) Patients had a history of malignancy within five years prior to ESCC diagnosis. Finally, 93 patients diagnosed with ESCC receiving preoperative CCRT followed by an esophagectomy were identified. Pretreatment staging included a computed tomography (CT) scan of the chest and abdomen or/and an endoscopic ultrasound (EUS). Patients were evaluated by a multidisciplinary team including a thoracic surgeon, a radiation oncologist, a medical oncologist, a gastroenterologist and a radiologist. The clinical staging was determined according to the 7th American Joint Committee on Cancer (AJCC) staging system (Supplementary Table S1) [25]. Overall survival was computed from the date of diagnosis until death or the last follow-up. Disease-free survival was calculated from the time of the esophagectomy to the diagnosis of recurrent disease or death without evidence of disease recurrence, censoring the date of death.
2.2. Treatment Plan

The protocol for preoperative CCRT was described as previously [2]. A post-treatment CT scan was performed to evaluate the treatment response within 3–4 weeks from the end of radiotherapy. The multidisciplinary team reviewed the clinical information to make decisions for an operation or not. If the lesions were classified as resectable, surgery was advised approximately 6–10 weeks from the end of preoperative CCRT. Surgery included a radical esophagectomy with cervical esophagogastronomy or an Ivor Lewis esophagectomy with intrathoracic anastomosis, two-field lymphadenectomy, reconstruction of the digestive tract with a gastric tube and pylorus drainage procedures. The pCR was defined as the complete disappearance of all viable cancer cells in all surgical specimens including the esophageal lesion and lymph nodes.

2.3. Immunohistochemistry (IHC)

The immunoperoxidase technique using 4 µm slides of formalin-fixed, paraffin-embedded tissue sections was performed for IHC staining. In summary, deparaffinization and rehydration were performed first. For antigen retrieval, 10 mM citrate buffer (pH 6.0) for a heat-induced epitope retrieval in a hot water bath (95 °C) was used for 20 min. To block endogenous peroxidase activity, 0.3% hydrogen peroxide was used for 15 min. Then, the slides were put in blocking buffer with 1% goat serum for 1 h at room temperature. Next, we incubated the slides with a galectin-1 primary antibody (HPA000646; Sigma-Aldrich, St. Louis, MO, USA) at a 1:400 dilution for 40 min at room temperature. The LSAB2 kit (Dako, Carpinteria, CA, USA) followed by hematoxylin for counterstaining was used for immunodetection. Human melanoma was used as a positive control [18]. The negative control was an incubation without the primary antibody. The IHC interpretation was carried out independently by two pathologists (S.L.W. and W.T.H) without any clinico-pathological information. Galectin-1 staining was graded as no, faint, moderate and strong according to the intensity. Both moderate and strong staining intensities were considered positive. The galectin-1 staining was scored as follows: score 0: no or <10% positive staining; score 1: 10% to <40% positive staining; score 2: 40% to <70% positive staining; and score 3: ≥70% positive staining. Both scores 2 and 3 were defined as an overexpression of galectin-1 [18].

2.4. Statistical Analysis

The chi-square/Fisher’s exact tests were used to compare the proportion between the two groups. A multivariate analysis of pCR was calculated by logistic regression. The Kaplan–Meier method was used for the univariate survival analysis, and the statistical difference between different groups was tested by a log-rank test. The multivariate survival analysis was computed by a Cox regression model with a stepwise forward fashion to analyze the relative prognostic significance of the parameters. For all analyses, two-sided tests of significance were used with p < 0.05 being considered significant. A statistical analysis was performed using the IBM SPSS Statistics, version 17.0 (IBM Corp., Armonk, NY, USA) software package.

3. Results

3.1. Patient Characteristics

The patient characteristics are shown in Table 1. The median periods of follow-up were 86 months (range, 63.5–143.9 months) for the 20 survivors. The five-year overall and disease-free survival rates were 28% and 20%, respectively. Among these 93 patients, 23 (25%) patients achieved pCR after preoperative CCRT. The five-year overall and disease-free survival rates were 57% and 48% in patients with pCR, respectively. The corresponding rates were 19% and 11% in patients without pCR.
Table 1. Clinicopathologic features of patients (n = 93).

| Parameters                                      | No. of Cases (Percentage) |
|------------------------------------------------|---------------------------|
| Age (years) (mean: 53.2, median: 52, range: 37–77) |                           |
| <50                                            | 35 (38%)                  |
| 50 ≤ Age < 60                                  | 35 (38%)                  |
| 60 ≤ Age < 70                                  | 19 (20%)                  |
| 70 ≤ Age                                       | 4 (4%)                    |
| Sex                                            |                           |
| Male                                           | 91 (98%)                  |
| Female                                         | 2 (2%)                    |
| Clinical T classification                       |                           |
| T2                                             | 9 (10%)                   |
| T3                                             | 41 (44%)                  |
| T4                                             | 43 (46%)                  |
| Clinical N classification                       |                           |
| N0                                             | 23 (25%)                  |
| N1                                             | 30 (32%)                  |
| N2                                             | 29 (31%)                  |
| N3                                             | 11 (11%)                  |
| Clinical 7th AJCC stage                        |                           |
| II                                             | 23 (25%)                  |
| III                                            | 70 (75%)                  |
| Tumor grade                                    |                           |
| 1                                              | 16 (17%)                  |
| 2                                              | 54 (58%)                  |
| 3                                              | 23 (25%)                  |
| Primary tumor location                         |                           |
| Upper                                          | 13 (14%)                  |
| Middle                                         | 46 (49%)                  |
| Lower                                          | 34 (37%)                  |
| Galectin-1 expression                          |                           |
| Low expression                                 | 47 (51%)                  |
| Overexpression                                 | 46 (49%)                  |
| Surgical margin                                |                           |
| Negative                                       | 77 (83%)                  |
| Positive                                       | 16 (17%)                  |
| pCR                                            |                           |
| Absent                                         | 70 (75%)                  |
| Present                                        | 23 (25%)                  |

3.2. Correlation between Clinicopathological Parameters and the Expression of Galectin-1

The correlation between clinicopathological parameters and the expression of galectin-1 is summarized in Table 2. Among the 93 patients collected, 46 patients (49%) showed “overexpression” for galectin-1 expression, and the others showed “low expression” (Figure 1). We did not observe any association between galectin-1 expression and any clinicopathologic parameters including age, primary tumor location, histological grade, AJCC 7th staging, T classification and N classification.

3.3. Correlation between Clinicopathological Parameters and Pathological Complete Response

The relationship between the clinicopathological parameters and the response of chemoradiotherapy is summarized in Table 3. Low galectin-1 expression (p = 0.01) was significantly associated with pCR after preoperative chemoradiotherapy. The clinical 7th AJCC stage (stage II versus stage III) reached a trend (p = 0.065). The logistic model showed that low galectin-1 expression (p = 0.013, hazard ratio: 3.778, 95% confidence interval: 1.330–10.773) was independently correlated with pCR after chemoradiotherapy.
Table 2. Associations between galectin-1 expression and clinicopathologic parameters.

| Parameters                          | Category | Galectin-1 Expression | \( p \) Value |
|-------------------------------------|----------|-----------------------|---------------|
|                                     |          | Low Expression        | Overexpression|               |
| Age                                 | <52 y/o  | 28                    | 22            | 0.35          |
|                                     | ≥52 y/o  | 29                    | 24            |               |
| Clinical T classification           | T2/3     | 29                    | 21            | 0.12          |
|                                     | T4       | 18                    | 25            |               |
| Clinical N classification           | N0       | 14                    | 9             | 0.25          |
|                                     | N1/2/3   | 33                    | 37            |               |
| Clinical N classification           | N0/1     | 29                    | 24            | 0.35          |
|                                     | N2/3     | 18                    | 22            |               |
| Clinical 7th AJCC stage             | II       | 14                    | 9             | 0.25          |
|                                     | III      | 33                    | 37            |               |
| Tumor grade                         | 1/2      | 35                    | 35            | 0.86          |
|                                     | 3        | 12                    | 11            |               |
| Primary tumor location               | Upper/Middle | 27                  | 32          | 0.23          |
|                                     | Lower    | 20                    | 14            |               |

Figure 1. Immunohistochemical staining of galectin-1. (A) Representative example of low galectin-1 expression in esophageal squamous cell carcinoma. (B) Representative example of galectin-1 overexpression in esophageal squamous cell carcinoma. Original magnification, 200×.

3.4. Survival Analyses

Correlations of the clinicopathological parameters and galectin-1 expression with overall survival and disease-free survival are summarized in Table 4. Univariate analyses demonstrated that galectin-1 overexpression \( (p = 0.004, \text{Figure 2A}) \), AJCC 7th stage III \( (p = 0.036) \) and a positive surgical margin \( (p = 0.001) \) were significantly associated with inferior overall survival. Additionally, galectin-1 overexpression \( (p = 0.01, \text{Figure 2B}) \), AJCC 7th stage III \( (p = 0.018) \), clinical N classification, N2/N3 \( (p = 0.038) \) and a positive surgical margin \( (p = 0.001) \) were significantly correlated with worse disease-free survival. In multivariate analyses, galectin-1 overexpression \( (p = 0.002, \text{hazard ratio: 2.098, 95\% confidence interval: 1.310–3.359, Table 5}) \) and a positive surgical margin \( (p = 0.001, \text{hazard ratio: 2.778, 95\% confidence interval: 1.555–4.950, Table 5}) \) represented independent adverse prognosticators for inferior overall survival. Besides, galectin-1 overexpression \( (p = 0.01, \text{hazard ratio: 1.839, 95\% confidence interval: 1.157–2.923, Table 5}) \) and a positive surgical margin \( (p = 0.001, \text{hazard ratio: 2.577, 95\% confidence interval: 1.462–4.545, Table 5}) \) were also independent adverse prognosticators for worse disease-free survival. The five-year overall and disease-free survival rates were 20% and 11% in patients with galectin-1 overexpression, and 36% and 30% in patients with low galectin-1 expression.
Table 3. Associations between the pathological complete response and clinicopathologic parameters.

| Parameters                  | Category   | Pathological Complete Response | Present | Absent | p Value |
|-----------------------------|------------|--------------------------------|---------|--------|---------|
| Age                         | <52y/o     | 7                              | 33      | 0.16   |
|                             | ≥52y/o     | 16                             | 37      |         |         |
| Clinical T classification   | T2/3       | 15                             | 35      | 0.20   |
|                             | T4         | 8                              | 35      |         |         |
| Clinical N classification   | N0         | 8                              | 15      | 0.20   |
|                             | N1/2/3     | 15                             | 55      |         |         |
| Clinical N classification   | N0/1       | 16                             | 37      | 0.16   |
|                             | N2/3       | 7                              | 33      |         |         |
| Clinical 7th AJCC stage     | II         | 9                              | 14      | 0.065  |
|                             | III        | 14                             | 56      |         |         |
| Tumor grade                 | 1/2        | 18                             | 52      | 0.70   |
|                             | 3          | 5                              | 18      |         |         |
| Primary tumor location      | Upper/Middle| 12                           | 47      | 0.20   |
|                             | Lower      | 11                             | 23      |         |         |
| Galectin-1                  | Low expression | 17                          | 30      | 0.01 * |
|                             | Overexpression | 6                             | 40      |         |         |

* Statistically significant. x^2 test was used for the statistical analysis.

Table 4. Results of the univariate analysis of the prognostic factors for overall survival and disease-free survival.

| Factors                        | No. of Patients | Overall Survival (OS) | Disease-Free Survival (DFS) |
|--------------------------------|-----------------|------------------------|----------------------------|
|                                |                 | 5-year OS Rate (%)     | 5-year DFS Rate (%)        | p Value |
| Age                            |                 |                        |                           |         |
| <52y/o                         | 40              | 25%                    | 20%                       | 0.93    |
| ≥52y/o                         | 53              | 30%                    | 21%                       | 0.99    |
| Clinical T classification      |                 |                        |                           |         |
| T2/3                           | 50              | 34%                    | 24%                       | 0.13    |
| T4                             | 43              | 21%                    | 16%                       | 0.078   |
| Clinical N classification      |                 |                        |                           |         |
| N0                             | 23              | 44%                    | 30%                       | 0.22    |
| N1/2/3                         | 70              | 23%                    | 17%                       | 0.12    |
| Clinical N classification      |                 |                        |                           |         |
| N0/1                           | 53              | 36%                    | 25%                       | 0.093   |
| N2/3                           | 40              | 18%                    | 15%                       | 0.038 * |
| Clinical 7th AJCC stage        |                 |                        |                           |         |
| II                             | 23              | 52%                    | 35%                       | 0.036 * |
| III                            | 70              | 20%                    | 16%                       | 0.018 * |
| Tumor grade                    |                 |                        |                           |         |
| 1/2                            | 70              | 29%                    | 21%                       | 0.49    |
| 3                              | 23              | 26%                    | 17%                       | 0.75    |
| Primary tumor location         |                 |                        |                           |         |
| Upper/Middle                   | 59              | 29%                    | 20%                       | 0.83    |
| Lower                          | 34              | 27%                    | 21%                       | 0.67    |
| Surgical margin                |                 |                        |                           |         |
| Negative                       | 77              | 34%                    | 25%                       | 0.001 * |
| Positive                       | 16              | 0%                     | 0%                        | 0.001 * |
| Galectin-1                     |                 |                        |                           |         |
| Low expression                 | 47              | 36%                    | 30%                       | 0.004 * |
| Overexpression                 | 46              | 20%                    | 11%                       | 0.01 *  |

* Statistically significant.
Cancers 2021, 13, x 7 of 11

Figure 2. Kaplan–Meier plots to predict (A) overall survival and (B) disease-free survival according to galectin-1 immuno-expression. Esophageal squamous cell carcinoma patients with galectin-1 overexpression have significantly shorter overall survival and disease-free survival than those with low galectin-1 expression.

Table 5. Results of the multivariate Cox regression analysis for overall survival and disease-free survival in 93 patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.

| Factors                  | Overall Survival   | Disease-free Survival |
|--------------------------|--------------------|-----------------------|
|                          | HR (95% CI)        | p Value               | HR (95% CI)        | p Value               |
| Galectin-1 overexpression| 2.098              | 0.002 *               | 1.839              | 0.01 *                |
|                          | (1.310–3.359)      |                       | (1.157–2.923)      |                       |
| Positive surgical margin | 2.778              | 0.001 *               | 2.577              | 0.001 *               |
|                          | (1.555–4.950)      |                       | (1.462–4.545)      |                       |

HR, hazard ratio; 95% CI, 95% confidence interval; * Statistically significant.

4. Discussion

The majority of patients with ESCC have advanced disease when they are diagnosed. The outcome of patients with locally advanced ESCC treated with preoperative CCRT is unsatisfactory, with a five-year survival of around 30% [5–7].

To the best of our knowledge, the present study is the first report that galectin-1 is an independent prognosticator in locally advanced ESCC following preoperative CCRT. Our findings suggest that galectin-1 may be a significant biomarker for patients with ESCC treated with preoperative CCRT. Previous several studies have revealed that galectin-1 is associated with poor prognosis in numerous human cancers. Sausez et al. [26] reported that galectin-1 overexpression is a negative prognosticator in patients with laryngeal squamous cell carcinoma. Wu et al. [27] found that galectin-1 overexpression was associated with poor prognosis in patients with hepatocellular carcinoma following resection. In patients with clear cell renal cell carcinoma, White et al. [15] also showed that galectin-1 overexpression was correlated with shorter disease-free survival. However, the significance of galectin-1 expression on the prognosis of patients with locally advanced ESCC treated with preoperative CCRT remains unknown. Thus, we focused on these ESCC patients and determined the significance of galectin-1 expression. Interestingly, we found that galectin-1 overexpression was significantly correlated with poor overall and disease-free survival in the univariate analysis and that it remained independent in the multivariate analysis.

In the present study, we found that there was a significant association between galectin-1 expression and CCRT response, which may partially explain the poor overall and disease-free survival in patients with galectin-1 overexpression. Patients with galectin-1 over-
expression had a lower pCR rate than those with low galectin-1 expression. Among 47 patients with low galectin-1 expression, 17 (36%) patients had pCR after preoperative CCRT. However, only six (13%) of 46 patients with galectin-1 overexpression got pCR. Recently, for patients with locally advanced ESCC, treatment modalities of definitive or preoperative CCRT followed by surgery have been advocated in many medical centers [2]. After CCRT, no viable tumors are observed in 20–40% of resected esophageal tumor specimens, and it is associated with therapeutic long-term survival benefits [5–7]. On the other hand, preoperative CCRT increases the perioperative morbidity and mortality [28]. The ability to identify patients whose tumor responds to CCRT could allow for a more appropriate decision for multimodality treatment options. Our results indicate that for locally advanced ESCC patients with galectin-1 overexpression, esophagectomy is suggested after chemoradiotherapy if the disease is operable. Our results showed that galectin-1 overexpression was associated with a poor response to CCRT in patients with ESCC. With regard to radiotherapy, Huang et al. [18,29] reported that galectin-1 was an independent prognostic factor for local recurrence and survival after definitive radiotherapy for patients with squamous cell carcinoma of the uterine cervix and that galectin-1 may mediate radioresistance through the H-Ras-dependent pathway involved in DNA damage repair. Chou et al. [21] also found that galectin-1 was a poor prognostic factor in patients with glioblastoma multiforme receiving radiotherapy. Kuo et al. [24] reported that galectin-1 could mediate radiation-related lymphopenia and attenuate the radiation response of non-small cell lung cancer. As for chemotherapy, cisplatin plus 5-FU was the most used regimen during CCRT in our study. Chung et al. [23] revealed that galectin-1 promoted the chemotherapeutic resistance of cisplatin in lung cancer by upregulating p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and cyclooxygenase-2. Su et al. [19] found that galectin-1-induced autophagy facilitated cisplatin resistance in hepatocellular carcinoma. Zhang et al. [30] showed that lncRNA small nucleolar RNA host gene 22 contributed to the chemotherapeutic resistance of cisplatin and paclitaxel through the miR-2467/galectin-1 signaling pathway in epithelium ovarian carcinoma. Gao et al. [31] reported that galectin-1 knockdown enhanced the cisplatin sensitivity of neuroblastoma cells by inhibiting autophagy. The above findings suggest that galectin-1 plays an important role in the resistance to radiotherapy and chemotherapy. Therefore, more studies are encouraged to further elucidate the role of galectin-1 in the resistance to radiotherapy and chemotherapy.

For patients with locally advanced ESCC receiving preoperative CCRT, 10–20% patients cannot receive planned esophagectomy due to the development of distant metastases, severe toxicity of preoperative CCRT, patient choice or poor performance status after preoperative CCRT [3,4]. Most of them did not receive the planned esophagectomy due to the development of distant metastases during preoperative CCRT. In the present study, we excluded ESCC patients without a planned esophagectomy after preoperative CCRT. We only enrolled ESCC patients receiving preoperative CCRT followed by a planned esophagectomy because we wanted to evaluate whether galectin-1 expression could predict the response of CCRT, and we suggested that pCR may be the best and clear-cut surrogate marker to represent the response of CCRT. For patients developing distant metastases during preoperative CCRT, their primary tumors may get a good response to CCRT, which highlights the importance of chemotherapy resistance instead of radiotherapy resistance.

Our study has some limitations. First, this was a retrospective study. Second, our observations were limited by the relatively small number of patients.

5. Conclusions

Our study showed that galectin-1 overexpression is independently associated with a poor response and worse prognosis in patients with ESCC who were treated with preoperative chemoradiotherapy. Therefore, galectin-1 might be a potential target for therapeutic intervention in ESCC patients who are treated with multimodalities.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13133147/s1, Table S1: American Joint Committee on Cancer (AJCC) TNM Classification of Carcinoma of the Esophagus and Esophagogastric Junction (7th ed, 2010)

Author Contributions: S.-H.L., Y.-M.W. and E.-Y.H. designed the study. S.-H.L., Y.-H.C., H.-I.L., C.-M.L., C.-C.H. and Y.-M.W. performed the data collection. S.-H.L., Y.-H.C. and E.-Y.H. performed the statistical analysis. S.-H.L. and E.-Y.H. wrote the original draft. C.-C.H. and E.-Y.H. supervised the project. All authors helped in revising and editing the manuscript through critical feedback. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partially funded by a grant of the Chang-Gung Medical Research Project (CMRPG8)0403, CMRPG8K0492, and CMRPG8K1291.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Chang Gung Medical Foundation. (protocol code 20210009B0 and date of approval 12 January 2021).

Informed Consent Statement: Written informed consent of the patients or their families was waived for this kind of retrospective study by the Chang Gung Medical Foundation Institutional Review Board.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to ethical restrictions.

Acknowledgments: We thank the Tissue Bank Core Lab at Kaohsiung Chang Gung Memorial Hospital (CLRPG8B0033 and CLRPG8E0161) for excellent technical support.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Term                           | Abbreviation |
|-------------------------------|--------------|
| Esophageal squamous cell carcinoma | ESCC         |
| Concurrent chemoradiotherapy   | CCRT         |
| Pathological complete response | pCR          |
| Immunohistochemistry           | IHC          |
| American Joint Committee on Cancer | AJCC       |
| Computed tomography            | CT           |
| Endoscopic ultrasound          | EUS          |

References

1. Li, S.H.; Chen, C.H.; Lu, H.I.; Huang, W.T.; Tien, W.Y.; Lan, Y.C.; Lee, C.C.; Chen, Y.H.; Huang, H.Y.; Chang, A.Y.; et al. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery 2015, 157, 570–580. [CrossRef]
2. Lu, H.I.; Li, S.H.; Huang, W.T.; Rau, K.M.; Fang, F.M.; Wang, Y.M.; Lin, W.C.; Tien, W.Y. A comparative study of isolated and metachronous oesophageal squamous cell carcinoma with antecedent upper aerodigestive tract cancer. Eur. J. Cardiothorac. Surg. 2013, 44, 860–865. [CrossRef] [PubMed]
3. Bedenne, L.; Michel, P.; Bouche, O.; Milan, C.; Mariette, C.; Conroy, T.; Pezet, D.; Roulet, B.; Seitz, J.F.; Herr, J.P.; et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 2007, 25, 1160–1168. [CrossRef]
4. Stahl, M.; Stuschke, M.; Lehmann, N.; Meyer, H.J.; Walz, M.K.; Seeber, S.; Klump, B.; Budach, W.; Teichmann, R.; Schmitt, M.; et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J. Clin. Oncol. 2005, 23, 2310–2317. [CrossRef]
5. Berger, A.C.; Farma, J.; Scott, W.J.; Freedman, G.; Weiner, L.; Cheng, J.D.; Wang, H.; Goldberg, M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J. Clin. Oncol. 2005, 23, 4330–4337. [CrossRef]
6. Li, S.H.; Huang, E.Y.; Lu, H.I.; Huang, W.T.; Yen, C.C.; Huang, W.C.; Chen, C.H. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 2012, 144, 1352–1359. [CrossRef]
7. Li, S.H.; Rau, K.M.; Lu, H.I.; Wang, Y.M.; Tien, W.Y.; Liang, J.L.; Lin, W.C. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. Eur. J. Cardiothorac. Surg. 2012, 42, 958–964. [CrossRef]
8. Barondes, S.H.; Castronovo, V.; Cooper, D.N.; Cummings, R.D.; Drickamer, K.; Feizi, T.; Gitt, M.A.; Hirabayashi, J.; Hughes, C.; Kasai, K.; et al. Galectins: A family of animal beta-galactoside-binding lectins. *Cell* **1994**, *76*, 597–598. [CrossRef]

9. Scott, K.; Weinberg, C. Galectin-1: A bifunctional regulator of cellular proliferation. *Glycoconjug. J.* **2004**, *19*, 467–477. [CrossRef]

10. Hughes, R.C. Galectins as modulators of cell adhesion. *Biochimie* **2001**, *83*, 667–676. [CrossRef]

11. Brandt, B.; Abou-Eladab, E.F.; Tiedge, M.; Walzel, H. Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death. *Cell Death Dis.* **2010**, *1*, e23. [CrossRef]

12. Croci, D.O.; Salatino, M.; Rubinstein, N.; Cerliani, J.P.; Cavallin, L.E.; Leung, H.J.; Ouyang, J.; Ilarregui, J.M.; Toscano, M.A.; Domaica, C.I.; et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. *J. Exp. Med.* **2012**, *209*, 1985–2000. [CrossRef]

13. Jung, T.Y.; Jung, S.; Ryu, H.H.; Jeong, Y.I.; Jin, Y.H.; Jin, S.G.; Kim, I.Y.; Kang, S.S.; Kim, H.S. Role of galectin-1 in migration and invasion of glioblastoma multiforme cell lines. *J. Neurosurg.* **2008**, *109*, 273–284. [CrossRef]

14. Zhao, X.Y.; Chen, T.T.; Xia, L.; Guo, M.; Xu, Y.; Yue, F.; Jiang, Y.; Chen, G.Q.; Zhao, K.W. Hypoxia inducible factor-1 mediates expression of galectin-1: The potential role in migration/invasion of colorectal cancer cells. *Carcinogenesis* **2010**, *31*, 1367–1375. [CrossRef]

15. White, N.M.; Masui, O.; Newsted, D.; Scorilas, A.; Romaschin, A.D.; Bjarnason, G.A.; Siu, K.W.; Yousef, G.M. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. *Br. J. Cancer* **2014**, *110*, 1250–1259. [CrossRef]

16. Kuo, P.; Le, Q.T. Galectin-1 links tumor hypoxia and radiotherapy. *Glycobiotherapy* **2014**, *24*, 921–925. [CrossRef]

17. Ikeda, Y.; Hisano, H.; Nishikawa, Y.; Nagasaki, Y. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors. *Mol. Pharm.* **2016**, *13*, 2283–2289. [CrossRef] [PubMed]

18. Huang, E.Y.; Chanchien, C.C.; Lin, H.; Wang, C.C.; Wang, C.J.; Huang, C.C. Galectin-1 is an independent prognostic factor for local recurrence and survival after definitive radiotherapy for patients with squamous cell carcinoma of the uterine cervix. *Int. J. Radiat. Oncol. Biol. Phys.* **2013**, *87*, 975–982. [CrossRef]

19. Su, Y.C.; Davuluri, G.V.; Chen, C.H.; Shiau, D.C.; Chen, C.C.; Chen, C.L.; Lin, Y.S.; Chang, C.P. Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. *PLoS ONE* **2016**, *11*, e0148408. [CrossRef]

20. Messaoudi, K.; Clavreul, A.; Lagarce, F. Toward an effective strategy in glioblastoma treatment. Part I: Resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. *Drug Discov. Today* **2015**, *20*, 899–905. [CrossRef] [PubMed]

21. Chou, S.Y.; Yen, S.L.; Huang, C.C.; Huang, E.Y. Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. *BMC Cancer* **2018**, *18*, 105. [CrossRef]

22. Zhang, P.; Zhang, P.; Shi, B.; Zhou, M.; Jiang, H.; Zhang, H.; Pan, X.; Gao, H.; Sun, H.; Li, Z. Galectin-1 overexpression promotes progression and chemoresistance in epithelial ovarian cancer. *Cell Dis. 2014*, *5*, e991. [CrossRef]

23. Chung, L.Y.; Tang, S.J.; Sun, G.H.; Chou, T.Y.; Yeh, T.S.; Yu, S.L.; Sun, K.H. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. *Clin. Cancer Res.* **2012**, *18*, 4037–4047. [CrossRef]

24. Kuo, P.; Bratman, S.V.; Shultz, D.B.; von Eyben, R.; Chan, C.; Wang, Z.; Say, C.; Gupta, A.; Loo, B.W., Jr.; Giaccia, A.J.; et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. *Clin. Cancer Res.* **2014**, *20*, 5558–5569. [CrossRef] [PubMed]

25. Edge, S.B.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A. (Eds.) *Esophagus and esophagogastric junction*. In *Aging*, 2019, 13, 3147. [CrossRef] [PubMed]

26. Reynolds, J.V.; Ravi, N.; Hollywood, D.; Kennedy, M.J.; Rowley, S.; Ryan, A.; Hughes, N.; Carey, M.; Byrne, P. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. *J. Thorac. Cardiovasc. Surg.* **2006**, *132*, 549–555. [CrossRef]

27. Saussez, S.; Decaestecker, C.; Lorferev, F.; Cucu, D.R.; Mortuaire, G.; Chevalier, D.; Wacreniez, A.; Kaltner, H.; Andre, S.; Toubeau, G.; et al. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. *Int. J. Oncol.* **2007**, *30*, 1109–1117. [CrossRef] [PubMed]

28. Chou, S.Y.; Yen, S.L.; Huang, C.C.; Huang, E.Y. Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. *BMC Cancer* **2018**, *18*, 105. [CrossRef]

29. Huang, E.Y.; Chen, Y.F.; Chen, Y.M.; Lin, I.H.; Wang, C.C.; Su, W.H.; Chiang, P.C.; Yang, K.D. A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. *Cell Death Dis.* **2012**, *3*, e251. [CrossRef]

30. Zhang, P.F.; Wu, J.; Luo, J.H.; Li, K.S.; Wang, F.; Huang, W.; Wu, Y.; Gao, S.P.; Zhang, X.M.; Zhang, P.N. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma. *Aging* **2019**, *11*, 8204–8216. [CrossRef]

31. Gao, J.; Wang, W. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells. *Chem. Biol. Interact.* **2019**, *297*, 50–56. [CrossRef] [PubMed]